A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Azacitidine (Primary) ; Sodium phenylbutyrate
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 10 May 2006 Status changed from in progress to completed.
- 08 Aug 2005 New trial record.